HIGH DOSE ACYCLOVIR VS VIDARABINE IN NEONATAL HERPES SIMPLEX INFECTION

高剂量阿昔洛韦与阿糖腺苷治疗新生儿单纯疱疹感染

• 批准号: 3783523
• 负责人: RICHARD J. WHITLEY
• 金额: --
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3783523
• 关键词: Herpes simplex disease; acyclovir; drug administration rate /duration; drug screening /evaluation; human subject; human therapy evaluation; infectious encephalitis; microorganism disease chemotherapy; newborn human (0-6 weeks); pediatric pharmacology

This collaborative study of neonatal herpes simplex virus infection will evaluate high dose acyclovir (60mg/kg/day) vs vidarabine (30mg/kg/day) for 21 days in the treatment of neonatal HSV infection in babies with encephalitis (CNS) or disseminated disease.

这项关于新生儿单纯疱疹病毒感染的合作研究将 评价大剂量阿昔洛韦(60 mg/kg/d)与阿达拉滨(30 mg/kg/d)的疗效 21天治疗新生儿单纯疱疹病毒感染的临床观察 脑炎(CNS)或播散性疾病。